戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  hemolytic anemia is the most common form of autoimmune hemolytic anemia.
2 elops anti-erythrocyte Abs and is a model of autoimmune hemolytic anemia.
3 tood disorder affecting 15% of patients with autoimmune hemolytic anemia.
4 dying within 3 to 5 wk from complications of autoimmune hemolytic anemia.
5 the BALB/c background, they rapidly die from autoimmune hemolytic anemia.
6 ion of autoantibodies and the development of autoimmune hemolytic anemia.
7 lement may be exploited to prevent and treat autoimmune hemolytic anemia.
8 ocytes by Kupffer cells in a murine model of autoimmune hemolytic anemia.
9 emissions in patients with severe refractory autoimmune hemolytic anemia.
10 taneous spleen rupture or to cure refractory autoimmune hemolytic anemia.
11 trial: one rejection event and an episode of autoimmune hemolytic anemia.
12      Reactive hemophagocytic syndrome (44%), autoimmune hemolytic anemia (33%), and lymphoma (22%) we
13                     One patient developed an autoimmune hemolytic anemia 4 years after transplantatio
14 tive and autoimmune disease characterized by autoimmune hemolytic anemia (AHA) and inflammatory bowel
15                                              Autoimmune hemolytic anemia (AHA) is a common complicati
16 itor changes, and signaling kinetics, during autoimmune hemolytic anemia (AIHA) and bone marrow failu
17 clones recovered ex vivo from a patient with autoimmune hemolytic anemia (AIHA) and characterize thei
18 (cITP) cases, and few data exist about it in autoimmune hemolytic anemia (AIHA) and Evans syndrome (E
19  retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated
20               Relapsing or occurring de novo autoimmune hemolytic anemia (AIHA) during pregnancy or p
21 he role of complement in the pathogenesis of autoimmune hemolytic anemia (AIHA) has been controversia
22 tly spontaneous autoimmune diseases, such as autoimmune hemolytic anemia (AIHA) in New Zealand Black
23                                              Autoimmune hemolytic anemia (AIHA) is a disease in which
24 resulting from the deletion of IL-2 in which autoimmune hemolytic anemia (AIHA) is a prominent featur
25                                              Autoimmune hemolytic anemia (AIHA) is an uncommon entity
26                                              Autoimmune hemolytic anemia (AIHA) is the result of incr
27 ops a genetically imposed severe spontaneous autoimmune hemolytic anemia (AIHA) that is very similar
28 zed cancer immunotherapy but also can induce autoimmune hemolytic anemia (AIHA), a severe disease wit
29                                           In autoimmune hemolytic anemia (AIHA), circulating red bloo
30 ond-line therapy in 23 patients with primary autoimmune hemolytic anemia (AIHA).
31 d cell (RBC) autoantibodies in patients with autoimmune hemolytic anemia (AIHA).
32             The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmu
33 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rh
34 mediated cytotoxicity in in vitro models for autoimmune hemolytic anemia and antibody-mediated reject
35 clonal B-cell lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory
36 disorder characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia.
37 en loss has been reported in the settings of autoimmune hemolytic anemia and transfusion of crossmatc
38 onic immune thrombocytopenic purpura, 19% of autoimmune hemolytic anemia, and 45% of Evans syndrome.
39 e treated similarly to those with idiopathic autoimmune hemolytic anemia, and additional therapy for
40 ons, including T and B lymphocyte depletion, autoimmune hemolytic anemia, and antibody-dependent enha
41 rplasia, autoimmune lymphocytic thyroiditis, autoimmune hemolytic anemia, and colitis.
42  splenomegaly, weight loss, life-threatening autoimmune hemolytic anemia, and hemophagocytosis.
43 oimmune disease, usually characterized by an autoimmune hemolytic anemia, and NZB genes are essential
44 plegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vacci
45 epitopes that emerge on erythrocytes lead to autoimmune hemolytic anemia, and the causative auto-IgM
46 is, serositis, neuropsychiatric involvement, autoimmune hemolytic anemia, anti-double-stranded DNA, a
47 Reversible posterior leukoencephalopathy and autoimmune hemolytic anemia are newly reported clinical
48                             Vasculitides and autoimmune hemolytic anemia are the two most common auto
49 eases like hereditary spherocytosis (HS) and autoimmune hemolytic anemia, but also with RBC senescenc
50               Transfusion, in the setting of autoimmune hemolytic anemia, can be a complicated and po
51 thrombosis, and protein-losing enteropathy), autoimmune hemolytic anemia, (catastrophic) antiphosphol
52            Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by complement
53 autoimmune hemolytic anemia (wAIHA) are rare autoimmune hemolytic anemias characterized by red blood
54 enotypes among descriptive diagnoses such as autoimmune hemolytic anemia, chronic immune thrombocytop
55          In immune thrombocytopenia and warm autoimmune hemolytic anemia, circulating immunoglobulin
56 th BALB/c mice, but which are predisposed to autoimmune hemolytic anemia, develop auto-antibodies to
57                                              Autoimmune hemolytic anemia developed in 4 patients 4 to
58                          One patient with an autoimmune hemolytic anemia developed PML after treatmen
59 ng these perturbed immune responses, such as autoimmune hemolytic anemia, immune thrombocytopenia, an
60 l as autoimmune complications manifesting as autoimmune hemolytic anemia, immune-mediated thrombocyto
61 ed patients with immune thrombocytopenia and autoimmune hemolytic anemia in the setting of acute infe
62  children (none with serious infection), and autoimmune hemolytic anemia in two (resolved with a ster
63 isorder is cold agglutinin disease (CAD), an autoimmune hemolytic anemia in which autoantibodies (col
64 d agglutinin disease is a difficult-to-treat autoimmune hemolytic anemia in which immunoglobulin M an
65 ory role of complement in the development of autoimmune hemolytic anemia is discussed.
66                      Patients with secondary autoimmune hemolytic anemia may be treated similarly to
67 essary, the therapies used for warm antibody autoimmune hemolytic anemia may be tried with less likel
68  as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, mouse models were used to e
69 severe refractory thrombocytopenia (n = 13), autoimmune hemolytic anemia (n = 15), and vasculitis (n
70                    ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n =
71  varies depending on whether the patient has autoimmune hemolytic anemia of warm antibody type, cold
72 include episodes of immune thrombocytopenia, autoimmune hemolytic anemia, or neutropenia, in addition
73 yositis/dermatomyositis, systemic sclerosis, autoimmune hemolytic anemia, pernicious anemia, and anky
74 rapeutic plasma exchange in the treatment of autoimmune hemolytic anemia remains uncertain.
75 syndrome, paroxysmal cold hemoglobinuria, or autoimmune hemolytic anemia secondary to an underlying d
76            Initial therapy for warm antibody autoimmune hemolytic anemia should be corticosteroids, s
77  the transfusion management of patients with autoimmune hemolytic anemia, specifically focusing on pu
78  arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, systemic lupus erythematosu
79 o discovered a potential early biomarker for autoimmune hemolytic anemia that is based on different l
80 le mechanistic link between the induction of autoimmune hemolytic anemia, the reduction in naive T ce
81  and its major complications: hypersplenism, autoimmune hemolytic anemia, thrombocytopenia, and neutr
82 nic purpura (ITP), hereditary spherocytosis, autoimmune hemolytic anemia, thrombotic thrombocytopenic
83 dies to FcRn, now in clinical trials in warm autoimmune hemolytic anemia to lower IgG antibodies and
84 crit level increased in 60% of patients with autoimmune hemolytic anemia undergoing successful laparo
85                                 Treatment of autoimmune hemolytic anemias varies depending on whether
86 oimmune hemolytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with bab
87 d agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) are rare autoimmune
88                                         Warm autoimmune hemolytic anemia (wAIHA) is caused by increas
89  +6 and +12; the response was better in warm autoimmune hemolytic anemia (WAIHA; overall response, 10
90                      Using a murine model of autoimmune hemolytic anemia, we defined the contribution
91 hamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with
92                                       Unlike autoimmune hemolytic anemia, which is characterized by a
93 tinues to be reported sporadically in severe autoimmune hemolytic anemia, with inconsistent results.